Aktuellt
SENASTE
FluoGuide continues to do a good job of managing the progress of its clinical program, in our view, with no delays to date except a small one that occurred because FG001 worked better in the clinical trial than expected. As the program gathers complexity, we think it will be harder to maintain this flawless track record, but this is an encouraging start. Meanwhile, new products and trials create upside potential to our valuation range.
LÄS MER
